Kristin Higgins, MD

Articles by Kristin Higgins, MD

Review of Treatment for Limited-Stage Small-Cell Lung Cancer

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, MedStar Georgetown University Hospital,Kristin Higgins, MD

July 6th 2020

Second- and Third-Line Treatment for ES-SCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, MedStar Georgetown University Hospital,Kristin Higgins, MD

July 6th 2020

Role of PCI Versus Brain MRI Surveillance in ES-SCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, MedStar Georgetown University Hospital,Kristin Higgins, MD

July 6th 2020

Expert Approaches to Treating Extensive Stage SCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, MedStar Georgetown University Hospital,Kristin Higgins, MD

July 6th 2020

KEYNOTE-604 and ECOG-ACRIN 5161 Trials for ES-SCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, MedStar Georgetown University Hospital,Kristin Higgins, MD

July 6th 2020

IMpower133 and CASPIAN Trials for Extensive Stage SCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, MedStar Georgetown University Hospital,Kristin Higgins, MD

July 6th 2020

Researchers Focus on Optimizing Radiotherapy for Locally Advanced NSCLC

ByKristin Higgins, MD

April 24th 2014

Locally advanced non-small cell lung cancer (NSCLC) remains a challenging disease to treat, with a 5-year survival rate for patients with unresectable stage III disease of approximately 20%, even after definitive radiation therapy and concurrent chemotherapy.

Latest Updated Articles

KEYNOTE-604 and ECOG-ACRIN 5161 Trials for ES-SCLC
Published: July 6th 2020 | Updated:
Review of Treatment for Limited-Stage Small-Cell Lung Cancer
Published: July 6th 2020 | Updated:
Role of PCI Versus Brain MRI Surveillance in ES-SCLC
Published: July 6th 2020 | Updated:
Expert Approaches to Treating Extensive Stage SCLC
Published: July 6th 2020 | Updated:
IMpower133 and CASPIAN Trials for Extensive Stage SCLC
Published: July 6th 2020 | Updated:
Second- and Third-Line Treatment for ES-SCLC
Published: July 6th 2020 | Updated:

Kristin Higgins, MD

Articles by Kristin Higgins, MD

Review of Treatment for Limited-Stage Small-Cell Lung Cancer

Second- and Third-Line Treatment for ES-SCLC

Role of PCI Versus Brain MRI Surveillance in ES-SCLC

Expert Approaches to Treating Extensive Stage SCLC

KEYNOTE-604 and ECOG-ACRIN 5161 Trials for ES-SCLC

IMpower133 and CASPIAN Trials for Extensive Stage SCLC

Researchers Focus on Optimizing Radiotherapy for Locally Advanced NSCLC

Latest Updated Articles

Trending on OncLive

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL

Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma

Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma

Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma